Showing 1 - 3 results of 3 for search 'A.-M. Fink', query time: 0.02s Refine Results
  1. 1
    S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

    S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by O. Al-Sawaf, C. Zhang, S. Robrecht, A. Kotak, N. Chang, A.-M. Fink, E. Tausch, C. Schneider, M. Ritgen, K.-A. Kreuzer, B. Chyla, B. Eichhorst, Y. Jiang, S. Stilgenbauer, M. Hallek, K. Fischer

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS

    P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS by P. Cramer, M. Fürstenau, A. Giza, S. Robrecht, E. Tausch, C. Schneider, C.-M. Wendtner, M. Hoechstetter, J. Schetelig, S. Böttcher, P. Dreger, A.-M. Fink, P. Langerbeins, O. Al-Sawaf, K. Fischer, S. Stilgenbauer, B. Eichhorst, M. Hallek

    Published 2022-06-01
    Get full text
    Article
  3. 3
    S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB

    S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB by O. Al-Sawaf, H. Y. Jin, C. Zhang, Y. Choi, S. Balasubramanian, S. Robrecht, A. Kotak, N. Chang, A.-M. Fink, E. Tausch, C. Schneider, M. Ritgen, K.-A. Kreuzer, B. Chyla, J. Paulson, B. Eichhorst, S. Stilgenbauer, Y. Jiang, M. Hallek, K. Fischer

    Published 2022-06-01
    Get full text
    Article

Search Tools: